Kalaris Therapeutics, Inc. KLRS 深 沪
等待开盘 05-22 09:30:00 美东时间
5.0901
+0.260
+5.39%
华盛通- 最 高5.1531
- 今 开4.75
- 成交量 2.45万股
- 最 低 4.75
- 昨 收 4.83
- 总市值 1.21亿
- 52周最高 11.88
- 市盈率 静 --
- 换手率 0.10%
- 52周最低 2.14
- 委 比 -43.60%
- 总股本 2379.23万
- 历史最高 1126.08
- 量 比 0.36
- 振 幅 8.35%
- 历史最低 4.52
- 每 手 1
- 风险率 2.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Citizens Maintains Market Outperform on Kalaris Therapeutics, Lowers Price Target to $25
Citizens analyst Jonathan Wolleben maintains Kalaris Therapeutics (NASDAQ:KLRS) with a Market Outperform and lowers the price target from $26 to $25.
05-13 22:24
Kalaris Therapeutics Q1 EPS $(0.46) Beats $(0.53) Estimate
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.53) by 13.21 percent. This is a 81.75 percent increase over losses of $(2.52) per share
05-12 20:09
美股大行评级 | 美国银行、摩根士丹利、JB亨特运输服务、PNC金融服务、Cheniere Energy等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持FibroBiologics"买入"评级，目标价从4美元升至8美元；摩根士丹利：维持Ultragenyx药业"超配"评级，目标价从50美元升至67美元
04-17 11:27
Kalaris Therapeutics Launches Up To $100M At-The-Market Stock Offering Agreement With TD Cowen
Up to $100,000,000Kalaris Therapeutics, Inc.Common StockWe have entered into a sales agreement with TD Securities (USA) LLC, or TD Cowen, relating to the sale of shares of our common stock, par value $0.0001 per share,
04-14 04:22
Kalaris Therapeutics CFO Matthew Gall Resigns, Effective April 14
https://www.sec.gov/ix?doc=/Archives/edgar/data/1754068/000119312526151215/d108368d8k.htm
04-11 04:16
Kalaris Therapeutics Q4 EPS $(0.44) Beats $(0.56) Estimate
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.56) by 21.01 percent.
03-17 20:13
Kalaris Therapeutics To Present Clinical Data From Phase 1 Study Of TH103 At 49th Annual Meeting Of Macula Society
Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data from its Phase 1 study of
01-29 05:23
美股大行评级 | 潜在涨幅63.56%！拜玛林制药获Truist Securities升目标价至100美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持拜玛林制药"买入"评级，目标价从80美元升至100美元；HC Wainwright & Co.：维持Savara"买入"评级，目标价从8美元升至10美元
2025-12-24 11:17
